The firm will evaluate CVHNLC in combination with Keytruda as a first-line and first-line maintenance treatment in NSCLC.

CureVac N.V. secured funding with GSK amid financial struggles, while a key patent win boosts stock. Click for why my ...

We recently published a list of 12 Best German Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where CureVac (NASDAQ:CVAC) stands against other best German ...

CureVac's amended patent survives BioNTech's challenge as EPO upholds validity. A German court will decide on infringement in ...

European Patent Office largely dismisses opposition filed by BioNTech SE in April 2023 challenging validity of EP 3 708 668 ...

Shares of CureVac climbed after the European Patent Office confirmed the validity of a patent that has been the subject of a lawsuit filed by BioNTech. The stock rose 7% to $2.99 on Friday. Shares ...

In a legal battle between BioNTech and CureVac, the European Patent Office declared a patent owned by CureVac ...

Novo Nordisk may miss sales expectations; federal judge fines Johnson & Johnson $1.64 billion in marketing case; CureVac mRNA ...

CureVac (CVAC) announced that the European Patent Office has confirmed the validity of the company’s European patent EP 3 708 668 B1 subject to ...

Leerink Partners analyst Mani Foroohar maintained a Hold rating on CureVac (CVAC – Research Report) on March 27. The company’s shares closed last Friday at $2.98. Discover the latest stocks ...

In this article, we are going to take a look at where CureVac (NASDAQ:CVAC) stands against other best German stocks to buy according to hedge funds. Germany’s economy is facing continued weakness.